abstract |
The invention is directed to therapeutic use of fibronectin antagonists to inhibit microbial intracellular invasion of or adherence to host mammalian cells. Co-administration of the inhibitory compound with an antibiotic, such as penicillin, that inefficiently permeates mammalian cell membranes increases the efficacy of the antibiotic therapy. |